Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

“Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.” ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.

Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect ~90% of ...